未登录
分享
收藏
分享
收藏
分享
收藏Tackling Challenging Data Integrity Topics in 2020: Update on Good Clinical Practice Perspectives from the US FDA and MHRA UK
Khin, Ni A.; Grandinetti, Cheryl; Dixey, Hayley; Yu, Bei; Skeete, Rachel; Ayalew, Kassa; Budwal-Jagait, Mandy; Cho, Seongeun-Julia; Dasgupta, Arindam; Fisher, Andrew; Kleppinger, Cynthia; Kronstein, Phillip D.; Martin, Jennifer; McGuinness, Michael; Mulinde, Jean; Vinter, Stephen; Wakelin-Smith, Jason; Walker, Paula; Francis, Gail
分享
收藏A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension
Kahn, Rene S.; Silverman, Bernard L.; DiPetrillo, Lauren; Graham, Christine; Jiang, Ying; Yin, Jiani; Simmons, Adam; Bhupathi, Vasudev; Yu, Bei; Yagoda, Sergey; Hopkinson, Craig; McDonnell, David
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏Data Integrity in Global Clinical Trials: Discussions From Joint US Food and Drug Administration and UK Medicines and Healthcare Products Regulatory Agency Good Clinical Practice Workshop
Khin, Ni A.; Francis, Gail; Mulinde, Jean; Grandinetti, Cheryl; Skeete, Rachel; Yu, Bei; Ayalew, Kassa; Cho, Seongeun-Julia; Fisher, Andrew; Kleppinger, Cynthia; Ayala, Ruben; Bonapace, Charles; Dasgupta, Arindam; Kronstein, Phillip D.; Vinter, Stephen
分享
收藏
分享
收藏NATALIZUMAB EXTENDED INTERVAL DOSING (EID) IS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) RISK COMPARED WITH STANDARD INTERVAL DOSING (SID) IN THE TOUCH® PRESCRIBING PROGRAM
Ryerson, Lana Zhovtis; Foley, John; Chang, Ih; Kister, Ilya; Cutter, Gary; Metzger, Ryan; Goldberg, Judith D.; Li, Xiaochun; Riddle, Evan; Smirnakis, Karen; Yu, Bei; Ren, Zheng; Hotermans, Christophe; Ho, Pei-Ran; Campbell, Nolan
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏